Acute Trials

Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution Study (DEFUSE 3)
Location: MedStar Washington Hospital Center
Purpose: This is a study to evaluate the hypothesis that FDA cleared thrombectomy devices plus medical management leads to superior clinical outcomes in acute ischemic stroke patients at 90 days when compared to medical management alone in appropriately selected subjects with the Target mismatch profile and an MCA (M1 segment) or ICA occlusion who can be randomized and have endovascular treatment initiated between 6-16 hours after last seen well.
Contact: For more information, contact Preethy Feit at (202) 877-1922

MR WITNESS: A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients

Location: MedStar Washington Hospital Center
Purpose: This study was jointly developed and is jointly led by investigators at Massachusetts General Hospital and the intramural division of NINDS. We are doing this research study to find out if Activase ® (also called alteplase or rt-PA) can safely be given to people with an acute ischemic stroke when their stroke onset was not witnessed making them ineligible for standard thrombolytic (clot busting) therapy. We also want to find out if rt-PA can help people recover better from their stroke.
Contact: For more information, contact Saman Farsad at saman.farsad@nih.gov.

Stroke Hyperglycemia Insulin Network Effort (SHINE)
Location: MedStar Washington Hospital Center
Purpose: The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial is a multicenter, randomized, controlled clinical trial of 1400 patients that will include approximately 60 enrolling sites. The study hypotheses are that treatment of hyperglycemic acute ischemic stroke patients with targeted glucose concentration (80mg/dL - 130 mg/dL) will be safe and result in improved 3 month outcome after stroke.
Contact: For more information, contact Leigh Demont at leigh.a.demont@medstar.net

Study of Procoagulation Markers in Stroke Patients (I-SPOT)
Location: MedStar Washington Hospital Center
Purpose: The Insights on Selected Procoagulation Markers and Outcomes in Stroke Trial (I-SPOT): Response to Insulin Administration and Blood Glucose Control proposal is designed to accompany the Stroke Hyperglycemia Insulin Network Effort (SHINE) clinical trial, a Phase III multicenter, randomized, controlled trial planning to determine the efficacy and validate the safety of glycemic control in stroke patients.
Contact: For more information, contact  Leigh Demont at leigh.a.demont@medstar.net